<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02677181</url>
  </required_header>
  <id_info>
    <org_study_id>81370666</org_study_id>
    <nct_id>NCT02677181</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT</brief_title>
  <official_title>Prospective Study of Combined ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>309th Hospital of Chinese People's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Naval General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Space Center Hospital, Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of combined ATG
      （antithymocyte globulin ） regimen for aGVHD(acute graft-versus-host disease ) prophylaxis in
      matched sibling donor peripheral blood stem cell transplantation (MSD-PBSCT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transplantation with G-CSF （Granulocyte colony stimulating factor ）mobilized peripheral blood
      stem cell (PBSCT) has been a stable transplant setting with matched sibling donor
      transplantation. Unmanipulated haploidentical donor PBSCT (haplo-PBSCT) has been applied in
      patients with hematologic malignancies. In our previous cohort study, haplo-PBSCT was
      associated with lower incidence of severe acute GVHD and extensive chronic GVHD compared with
      matched sibling donor PBSCT (MSD-PBSCT). Haplo-PBSCT has the same GVHD prophylaxis regimen
      with MSD-PBSCT, except ATG. It suggested the potential advantage of ATG in prophylaxis of
      GVHD and improvement of long-term quality of life of the transplant recipients, which
      motivate us to observe the efficacy of combined ATG regimen for GVHD prophylaxis in
      MSD-PBSCT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with aGVHD as assessed by acute graft versus host disease grading criteria (refer to Glucksberg criteria)</measure>
    <time_frame>three months</time_frame>
    <description>Acute graft versus host disease grading criteria (refer to Glucksberg criteria)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants relapse as assessed by NCCN (National Comprehensive Cancer Network )criteria</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS(disease-free survival )</measure>
    <time_frame>two years</time_frame>
    <description>disease-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRM(treatment-related mortality )</measure>
    <time_frame>two years</time_frame>
    <description>treatment-related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with cGVHD as assessed by acute graft versus host disease grading criteria (refer to Glucksberg criteria)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>aGVHD</condition>
  <arm_group>
    <arm_group_label>ATG combined regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATG combined regimen for prophylaxis of GVHD, includes ATG, MMF(Mycophenolate mofetil ),CsA (cyclosporin A) and MTX (methotrexate).
All recipients in this arm received ATG, CsA, mycophenolate mofetil, and short-term methotrexate for GVHD prophylaxis. ATG (Thymoglobuline, rabbit) was used on 2.5 mg/kg/d from days -4 to -3). CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no-ATG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>regimen for prophylaxis of GVHD without ATG. The regimen includes MMF,CsA and MTX.CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG</intervention_name>
    <description>rabbit ATG（Sanofi）</description>
    <arm_group_label>ATG combined regimen</arm_group_label>
    <other_name>Thymoglobuline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CsA</intervention_name>
    <description>cyclosporine (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered.</description>
    <arm_group_label>ATG combined regimen</arm_group_label>
    <arm_group_label>no-ATG</arm_group_label>
    <other_name>Neoral/Sandimmun</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30 for MSD-PBSCT.</description>
    <arm_group_label>ATG combined regimen</arm_group_label>
    <arm_group_label>no-ATG</arm_group_label>
    <other_name>MMF（Novartis）</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>short-term methotrexate</description>
    <arm_group_label>ATG combined regimen</arm_group_label>
    <arm_group_label>no-ATG</arm_group_label>
    <other_name>MTX(Pfizer)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. acute myeloid leukemia (AML) in CR1 (complete remission 1) or CR2 (complete remission
             2) phase regardless of cytogenetics;

          2. CML CP(chronic myelogenous leukemia , chronic phase);

          3. MDS-RAEB(myelodysplastic syndrome -refractory anemia with excess blasts ).

          4. All patients should aged 40 to 70 years

          5. Have matched sibling donor.

          6. Patients without any uncontrolled infections or without severe pulmonary, renal,
             hepatic or cardiac diseases .

        Exclusion Criteria:

          1. Patients aged less than 40 years old ;

          2. Patients with any uncontrolled infections or with severe pulmonary, renal, hepatic or
             cardiac diseases;

          3. AML patients with t (15;17);
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daihong Liu, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daihong Liu, Doctor</last_name>
    <phone>86-13681171597</phone>
    <email>daihongrm@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liping Dou, Doctor</last_name>
    <phone>86-13681207138</phone>
    <email>lipingruirui@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Liping Dou</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daihong Liu, doctor</last_name>
      <phone>86-13681171597</phone>
      <email>daihongrm@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Liping Dou, doctor</last_name>
      <phone>86-13681207138</phone>
      <email>lipingruirui@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Daihong Liu, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp TR, Waller EK, Litzow MR, Liesveld JL, Lazarus HM, Artz AS, Gupta V, Savani BN, McCarthy PL, Cahn JY, Schouten HC, Finke J, Ball ED, Aljurf MD, Cutler CS, Rowe JM, Antin JH, Isola LM, Di Bartolomeo P, Camitta BM, Miller AM, Cairo MS, Stockerl-Goldstein K, Sierra J, Savoie ML, Halter J, Stiff PJ, Nabhan C, Jakubowski AA, Bunjes DW, Petersdorf EW, Devine SM, Maziarz RT, Bornhauser M, Lewis VA, Marks DI, Bredeson CN, Soiffer RJ, Weisdorf DJ. Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant. 2012 Feb;18(2):280-8. doi: 10.1016/j.bbmt.2011.07.024. Epub 2011 Jul 31.</citation>
    <PMID>21810400</PMID>
  </reference>
  <reference>
    <citation>Rezvani AR, Storb RF. Prevention of graft-vs.-host disease. Expert Opin Pharmacother. 2012 Aug;13(12):1737-50. doi: 10.1517/14656566.2012.703652. Epub 2012 Jul 7. Review.</citation>
    <PMID>22770714</PMID>
  </reference>
  <reference>
    <citation>Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986 Mar 20;314(12):729-35.</citation>
    <PMID>3513012</PMID>
  </reference>
  <reference>
    <citation>Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009 Sep;10(9):855-64. doi: 10.1016/S1470-2045(09)70225-6. Epub 2009 Aug 18.</citation>
    <PMID>19695955</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Fu HX, Liu DH, Xu LP, Zhang XH, Chang YJ, Chen YH, Wang FR, Sun YQ, Tang FF, Liu KY, Huang XJ. Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial. Bone Marrow Transplant. 2014 Mar;49(3):426-33. doi: 10.1038/bmt.2013.191. Epub 2013 Dec 2.</citation>
    <PMID>24292519</PMID>
  </reference>
  <reference>
    <citation>Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O'Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2009 Nov;15(11):1422-30. doi: 10.1016/j.bbmt.2009.07.006. Epub 2009 Sep 1.</citation>
    <PMID>19822302</PMID>
  </reference>
  <reference>
    <citation>Storek J, Mohty M, Boelens JJ. Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 Jun;21(6):959-70. doi: 10.1016/j.bbmt.2014.11.676. Epub 2014 Dec 5. Review.</citation>
    <PMID>25482864</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>February 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Daihong Liu</investigator_full_name>
    <investigator_title>Head of Hematology departemnt in Chinese PLA General Hospital</investigator_title>
  </responsible_party>
  <keyword>ATG</keyword>
  <keyword>Matched sibling donor</keyword>
  <keyword>peripheral blood stem cell transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

